Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
Open accessThe DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.
Abstract
Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].](https://figures.cochat.ai/paper-figures/5ed93dc48917473ca30ad0e7a8a74987/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-1.jpg)
![Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/f800c1b6e6e24d13ba3b3f4e8509a14d/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-6.jpg)


![Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).](https://figures.cochat.ai/paper-figures/49d3fbddca5e428ea039b5bd152e68a0/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-4.jpg)


![Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/d4b1f0c188954fbdb7a6946c934ad246/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, sMRI and (18FDG)-PET indicate neurodegeneration or neuronal injury in the AT(N) framework with limitations in specifically diagnosing AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They cannot accurately differentiate AD from other neurodegenerative diseases with similar pathologies, such as frontotemporal degeneration and TDP-43 proteinopathies with medial temporal lobe atrophy.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8,9,10].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“, reporting decreased metabolism in the same two medial prefrontal regions [3,157] Altogether, these findings highlight the potential of FDG-PET for the longitudinal monitoring of AD progression.”
BackgroundInfluentialThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., Hee, M. R., Flotte, T., Gregory, K., Puliafito, C. A., et al. (1991) · Science · doi:10.1126/science.1957169 · Cited by 13,788
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676 · cited 7×
“Currently, two distinct biomarkers are used to assess Aβ pathology: the concentration of Aβ42 in the CSF and 2.3.2.”
MethodInfluentialAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“leading to the formation of senile plaques [7,20,82,83].”
BackgroundFunctional connectivity in the resting brain: a network analysis of the default mode hypothesis
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135058100 · Cited by 6,358
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“All other disease characteristics, such as the formation of NFTs out of hyperphosphorylated tau, and neurodegeneration, are seen a result of this accumulation [12,83,88].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 2×
“This statement is further underlined by the hypothetical model of dynamic biomarkers [77,78].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Items 301–351 of 351
Early detection of Alzheimer’s disease: Progress, challenges, and future outlook
Albayrak, A. (2026) · Disiplinlerarası Yenilik Araştırmaları Dergisi · doi:10.56723/dyad.1737746
Singh, S., & Ma, D. (2026) · SPIE Medical Imaging: Computer-Aided Diagnosis · doi:10.1117/12.3087877
“14 9 Starting from the raw MRI and PET volumes, all images are first spatially normalized by registering them to MNI template space to enable voxelwise correspondence across subjects and modalities.”
Konukoğlu, D. (2026) · International journal of medical biochemistry/International journal of medical biochemistry : · doi:10.14744/ijmb.2025.23281
“Blood-based biomarkers have therefore emerged as a practical and scalable complement—and in selected contexts, a partial alternative—to CSF-and PET-based diagnostics [8, 13, 18, 19].”
Nanofabricated Materials as Nanobiosensor: A Brief Overview
Saha, A., & Kumar, P. (2025) · Functional Thin Films and Energy Materials · doi:10.66000/3110-9772.2025.01.07
“It has been recently discovered that CSF biomarkers, including low concentrations of amyloid-beta and higher quantities of tau protein, can identify AD a decade before its initial manifestation of the disease (Oostveen et al ., 2021).”
Responsible AI for Health Governance: A Focus on Alzheimer's Patients
Garg, M., Juneja, A., Painuli, D., Mishra, D., Kumari, P., & Kumar, V. (2025) · International Conference on Innovations and Emerging Technologies in AI & Communication Systems (IETACS) · doi:10.1109/ietacs68750.2025.11385450
“The hallmark pathological features such as amyloid-beta plaques, neurofibrillary tangles that comprises hyperphosphorylated tau, and cortical atrophy are difficult to identify in early-stage diseases using standard diagnostic tools [4].”
Subhashini., K., Mahmood, A., Sharma, K., Sharma, A. P. G. K., Shafeeq, M., & Chaudhary, V. K. (2025) · International Conference on Innovations and Emerging Technologies in AI & Communication Systems (IETACS) · doi:10.1109/ietacs68750.2025.11385688
“The usage of CNNs for analysing brain MRIs has been found to be promising in detecting healthy subjects and patients with AD, and also apparent phases of cognitive decline [7].”
Leminie, A. A. (2026) · Preprints.org · doi:10.20944/preprints202603.0482.v1
Modeling of Sparse and Irregular Medical Image Time Series
Disch, N. (2026) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00038197
D, J. H., Gowda, J., Mallamma, T., & Prakash Goudanavar, S. O. P. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02299-7
Schmidt-Morgenroth, I. (2023) · theses.fr (ABES) · doi:10.70675/f89a7c1ez54acz49f7zbb58z4be7d3ab8c1f
Développement d'imagerie métabolique rapide et robuste chez l'homme à haut champ magnétique
Delebarre, T. (2024) · theses.fr (ABES) · doi:10.70675/9effc48ezfc98z4775zb242z4578ef0463cb
Role of Biomarker in Treating Alzheimer's Disease
Anand, P., Kumar, D., Gupta, S., Tiwari, J., & Singh, S. N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010006
WAHNet: Weighted Augmented Hybrid Network for Alzheimer’s Disease Detection
Agrawal, M., Poonam, K., Guha, R., & Chakrabarti, P. P. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-18480-1_15
Caon, B., Corti, M., Bonizzoni, F., & Antonietti, P. F. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.112182
Differences in Bilinguals and Multilinguals Diagnosed with Alzheimer's Disease
Carreon, N. R. (2024) · PDXScholar (Portland State University)
In vitro and in vivo inhibition of amyloid β aggregation by a Ru( ii )–naphthalene diimide complex
Tiburcio, M. A., Cali, M. P., Pereira, L. M. B., Graminha, A. E., Atienza‐Navarro, I., Vendruscolo, M., García-Alloza, M., & Carlos, R. M. (2026) · Dalton Transactions · doi:10.1039/d5dt02853a
Longitudinal study of Alzheimer's disease progression through MRI markers: A Systematic ReviewPreprint
Lotfalipour, M., Banifatemeh, M. S., Amini, B., Hemmat, F., Mirzakhani, P., Saemi, M., Solhirad, M., & Sadeghi, A. Z. (2026) · Research Square · doi:10.21203/rs.3.rs-9688545/v1
Duan, J., Yang, M., & Wang, Y. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1771993
Saxena, P., Kothiyal, P., & Ratan, P. (2026) · Neurological Research · doi:10.1080/01616412.2026.2673060
., K., & Jeetha, B. R. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.36s.46
Rahman, A., Prottoy, M. S. M., Chowdhury, M., Shanto, M. M. H., Hoque, M. A., & Mim, S. R. (2026) · Advances in intelligent systems research/Advances in Intelligent Systems Research · doi:10.2991/978-94-6239-664-7_3
Zhao, C., Huang, H., Xie, Y., Huang, J. W., & Zhou, W. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2606.13919
“Incorporating Positron Emission Tomography (PET) imaging, which provides complementary functional information [57], and developing multi-view graph matching techniques will allow the model to leverage both structural and functional modalities for a more comprehensive assessment of brain alterations…”
Wibowo, B. S., Yusuf, A. M., Mone, B. V., & Sari, S. A. (2026) · Jurnal Ilmu dan Teknologi Kesehatan · doi:10.32668/jitek.v13i2.2381
Tang, C., Shi, L., & Xu, S. (2026) · Biology · doi:10.3390/biology15131091
“AD is characterized by progressive brain atrophy, metabolic dysfunction, and cognitive decline, making neuroimaging an important tool for characterizing disease-related brain changes and supporting computer-aided diagnostic assessment [2,3].”
Khanjani, N., Venkatesan, M., Orlenko, A., Li, B., Peng, P.-C., Wang, Z. P., Obafemi-Ajayi, T., & Moore, J. H. (2026) · doi:10.2196/preprints.106586
Stites, S., Lee, K., Kuz, C., Mandell, D., Bogner, H., & Brown, R. T. (2026) · Current Psychiatry Reports · doi:10.1007/s11920-026-01704-1
Rodrigues, W. D. M. A., & Rodrigues, M. A. C. (2026) · COGNITIONIS Scientific Journal · doi:10.38087/2595.8801.882
Ali, J. B., Laamiri, N., Chaouech, L., Berghout, T., Bigan, C., & Besleaga, M. (2026) · International Conference on Control, Automation and Diagnosis (ICCAD) · doi:10.1109/iccad69956.2026.11643032
Aging as a Continuation of Development: A Hypothesis and Framework
Fernandez, F., Burke, S. N., & Nadel, L. (2026) · Perspectives on Psychological Science · doi:10.1177/17456916261469175
Activity Recognition using Magnet Sensors and its Applications in Elderly Care
Papel, J. F. (2024) · Institutional Repositories DataBase (IRDB)
Sarabia‐Vallejo, Á., Fuente-Tovar, M., Clerigué, J., López‐Alvarado, P., Ran, C., Martín, M. A., & Menéndez, J. C. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110475
Advances in Multimodal Deep Learning Models for Early Alzheimer's Disease Detection: A Survey
Zhang, J., Fei, Z., Zhou, W., & Fei, M. (2026) · International Conference on Machine Learning and Intelligent Computing · doi:10.1145/3829441.3829478
Hippocampal atrophy and its consequences in AD
Memudu, A. E., Ovwere, I. R., Funsho, I. I., Nwanama, K. E., Ighodaro, C. N., & Noufal, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.028
Mastropasqua, F. (n.d.) · CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)
Pereira, M. V. D. S., Alfredo, L. H. M., de Moraes, M. N., & de Jesus, J. R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.004
The Role Of MRI In Early Detection Of Neurodegenerative Diseases
Al-Shalail, G. A. M., Alshulayyel, G. A. M., Dosh, A. A. H., shahrani, K. S. A., Faya, A. M., Alharbi, O. M., almutiri, E. S. S., Alkhabari, S., & Alenazy, Y. A. (2025) · The Review of Diabetic Studies · doi:10.70082/4z9ynj07
ADVANCED COGNITIVE, MOLECULAR AND STRUCTURAL BIOMARKERS IN PRECLINICAL AND PRODROMAL DEMENTIA PHASES
Tondo, G. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Does structural MRI correlate with a stage of Alzheimer’s disease – a case report.
Gigineĭshvili, D. A., & Gogiashvili, I. (2025) · Translational and Clinical Medicine - Georgian Medical Journal
Latha, J. S. (2024) · Journal of Electrical Systems
Iqbal, R. (2025) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Multitarget approaches in the treatment of Alzheimer’s disease: A new strategy in drug design
Pereira, M. V. S., Ribeiro, I. S., Aquino, W. C. P., Alfredo, L. H. M., da Paixao, Y. F., Despaigne, A. A. R., de Moraes, M. N., & de Jesus, J. R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.07.005
Solar, K. G., Kashyap, S., Deom, N., Uludaǧ, K., Zotovic, L., Lanctôt, K. L., Black, S. E., & McAndrews, M. P. (2026) · Brain Imaging and Behavior · doi:10.1007/s11682-026-01208-9
“Our findings add to the expanding body of work supporting multimodal neuroimaging biomarkers for early detection and stratification in AD (Terry et al., 2015; van Oostveen et al., 2021; Johnson et al., 2012 ; Márquez & Yassa, 2019; Zetterberg & Bendlin, 2021; Veitch et al., 2022).”
Super-Cross-Reactive Recognition Enables Preclinical Diagnosis of Alzheimer’s Disease
Li, W., Li, J., Ning, X., Tian, J., Chen, F., Zhang, S.-X., Wang, Z.-H., Pan, Y., Zhang, W., & Guo, D. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c14717
Patel, P. R., Arumugam, P., & Mohan, D. (2026) · 2026 International Conference on Science Technology Engineering and Management (ICSTEM) · doi:10.1109/icstem68144.2026.11735485
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Carmona, S. F. F. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Lima, B. R., dos Santos, Y. T. P., Farias, G. C., Souza, E. F. R. D. L., de Lima, P. D. L., Quaresma, J. A. S., Vasconcelos, P. F. D. C., & de Sousa, J. R. (2026) · Immunologic Research · doi:10.1007/s12026-026-09873-0
Parviz, G. (2025) · Marmara University Open Access System
Kundryukova, K. V., Guzaerov, I. F., Zentsova, V. S., Gerasenkova, A. V., Gumerova, D. I., Morozova, V. A., Shamsutdinova, D. I., Mingaleeva, N. E., Akhmetzianov, A. I., Kadyrova, D. D., et al. (2026) · Ophthalmology Reports · doi:10.17816/ov707331
Kim, J., Han, S. S., Yoo, S.-H., Lee, D., Jang, J., Lee, H., Song, J., & Hoe, H. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71923
Metadata
- Authors
- van Oostveen, W. M., & de Lange, E. C. M.
- Affiliations
- Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 22
- Issue
- 4
- Pages
- 2110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7924338
- OpenAlex
- W3131910442
- Cited by
- 297
- References
- 232
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.